New Gold Bond® No Mess Powder Spray Introduced by Sanofi's Chattem
The same trusted formula in an easy aim spray
CHATTANOOGA, Tenn., May 6, 2013
CHATTANOOGA, Tenn., May 6, 2013 /PRNewswire/ --Gold Bond^® has been the gold
standard for beating the heat and staying cool and dry for generations. Now,
Chattem, Inc., the Consumer Healthcare Division of Sanofi US is introducing
the same trusted brand in a new, no mess powder spray that delivers the odor
and wetness protection of Gold Bond Powder in a convenient, easy-to-use spray.
The continuous spray delivers right where you want it – with a targeted stream
different from the traditional powder. So whether you're looking to stay cool
and dry for peak performance, or you just want to relieve and protect against
odor, you can count on Gold Bond's triple action formula. Afterall, it's
provided relief since 1908.
"The new Gold Bond No Mess Powder Spray is the same formula as Gold Bond
Powder, and the new product packaging -- an easy-to-hold spray can with a 360
degree continuous spray top -- allows people to use it in an even more
effective way," said John Stroud, Executive Vice President, Chattem.
The product is now available in drug, grocery and mass merchandise stores
Gold Bond No Mess Powder Spray Fast Facts:
oProduct benefits: Delivers the odor and wetness relief of Gold Bond Powder
in a convenient, easy-to-use spray. The product provides triple action
relief, cools on contact, absorbs moisture and soothes skin.
oWhen/How to Use: After shower, bath or exercise or whenever you want to
stay cool and dry, simply use Gold Bond No Mess Powder Spray for lasting
deodorant protection and that cool, refreshing feeling.
oWho Uses: People who want to stay comfortable while being active and
people engaging in outdoor activities: sports, work, hiking, music
festivals, summer sports camps, military, etc.
oProduct ingredients: Talc, starch, zinc oxide, fragrance, cooling and
soothing agents, and botanicals.
oAvailable in Two Formulas:
oClassic: Captures the feel, relief and scent of the original, classic
oFresh: An update on the classic. Same feel and relief, but with a
light, fresh fragrance.
oSize: 7 oz, 360 degree spray
oSuggested Retail Price/Availability: $7.99; on shelves next to Gold Bond
Powder at major retailers including Wal-Mart, Target and Walgreens.
About Gold Bond
Powerful, hard-working and trusted since 1908, Gold Bond is now in its second
century of healing. Gold Bond offers a broad line of products, including some
of the fastest growing hand and body lotions, as well as the top selling
medicated body powder, foot powder, foot cream, and foot pain cream in
America. For more information, visit Gold Bond on Facebook and Twitter.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer
healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and
operates in the United States as Sanofi US, also referred to as sanofi-aventis
U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us
or call 1-800-981-2491.
In March 2010, Chattem, Inc. became a wholly-owned subsidiary of the
sanofi-aventis Group as the consumer healthcare division of Sanofi US. Chattem
is more than 130 years old and is a leading manufacturer and marketer of
branded consumer healthcare products, toiletries and dietary supplements
across niche market segments in the United States. For more information,
please visit Chattem's website at www.chattem.com.
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Tel.: 908 981 6673
SOURCE Gold Bond
Press spacebar to pause and continue. Press esc to stop.